Showing results (201-210 of 408) with videos related to
Sort By:
Pageof 41
Blood|July 28, 2019
Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphomaYucai Wang, Brian K Link, Thomas E Witzig, et al.British Journal of Haematology|February 25, 2012
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphomaLuis F Porrata, Kay Ristow, Thomas M Habermann, et al.British Journal of Haematology|April 17, 2007
Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomasDeepti Behl, Kay Ristow, Svetomir N Markovic, et al.Blood|July 15, 2009
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disordersRyan A Wilcox, Andrew L Feldman, David A Wada, et al.American Journal of Hematology|March 16, 2010
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphomaPatrick B Johnston, David J Inwards, Joseph P Colgan, et al.European Journal of Haematology|August 2, 2006
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosisCarlo Visco, Gianpaolo Nadali, Theodoros P Vassilakopoulos, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemiaGrzegorz S Nowakowski, James D Hoyer, Tait D Shanafelt, et al.Leukemia & Lymphoma|July 7, 2007
Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51David M Kurtz, Loren K Tschetter, Jacob B Allred, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2002
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphomaThomas E Witzig, Leo I Gordon, Fernando Cabanillas, et al.Blood|May 31, 2002
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trialGregory A Wiseman, Leo I Gordon, Pratik S Multani, et al.Pageof 41